Terms: = Thyroid cancer AND ER, estrogen receptor AND Treatment
250 results:
1. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
[TBL] [Abstract] [Full Text] [Related]
2. Application of fluorocarbon nanoparticles of
Zhi L; Cheng C; Jing L; Zhi-Ping P; Lu Y; Yan T; Zhi-Gang W; Guo-Bing Y
J Nanobiotechnology; 2024 Mar; 22(1):107. PubMed ID: 38475902
[TBL] [Abstract] [Full Text] [Related]
3. A novel bystander effect in tamoxifen treatment: PPIB derived from ER+ cells attenuates ER- cells via endoplasmic reticulum stress-induced apoptosis.
Yang T; Li W; Zhou J; Xu M; Huang Z; Ming J; Huang T
Cell Death Dis; 2024 Feb; 15(2):147. PubMed ID: 38360722
[TBL] [Abstract] [Full Text] [Related]
4. HNRNPC promotes estrogen receptor-positive breast cancer cell cycle by stabilizing WDR77 mRNA in an m6A-dependent manner.
Xu W; Huang Z; Xiao Y; Li W; Xu M; Zhao Q; Yi P
Mol Carcinog; 2024 May; 63(5):859-873. PubMed ID: 38353359
[TBL] [Abstract] [Full Text] [Related]
5. Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer.
Sha R; Dong X; Yan S; Dai H; Sun A; You L; Guo Z
Sci Rep; 2024 Feb; 14(1):2908. PubMed ID: 38316885
[TBL] [Abstract] [Full Text] [Related]
6. Effects of postoperative antioxidants on the salivary glands in patients with thyroid cancer undergoing radioactive iodine-131 treatment.
Tong H; Yue R; Fang J; Li X; Yang S; Hou Y; Wang R; Zhang B; Liu H; Wu Z; Cheng Y
Nucl Med Commun; 2024 Apr; 45(4):312-320. PubMed ID: 38312062
[TBL] [Abstract] [Full Text] [Related]
7. Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect.
Li X; Zheng H; Ma C; Ji Y; Wang X; Sun D; Meng Z; Zheng W
Front Endocrinol (Lausanne); 2023; 14():1307325. PubMed ID: 38298190
[TBL] [Abstract] [Full Text] [Related]
8. Construction and validation of a prognostic nutritional index-based nomogram for predicting pathological complete response in breast cancer: a two-center study of 1,170 patients.
Qu F; Luo Y; Peng Y; Yu H; Sun L; Liu S; Zeng X
Front Immunol; 2023; 14():1335546. PubMed ID: 38274836
[TBL] [Abstract] [Full Text] [Related]
9. 2020 Annual Report of National Clinical Database-Breast cancer Registry: 10-year mortality of elderly breast cancer patients in Japan.
Sagara Y; Kumamaru H; Niikura N; Miyashita M; Konishi T; Iwamoto T; Sanuki N; Tanakura K; Nagahashi M; Hayashi N; Yoshida M; Kinukawa N; Watanabe C; Toi M; Saji S
Breast Cancer; 2024 Mar; 31(2):179-184. PubMed ID: 38180641
[TBL] [Abstract] [Full Text] [Related]
10. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
Pita JM; Raspé E; Coulonval K; Decaussin-Petrucci M; Tarabichi M; Dom G; Libert F; Craciun L; Andry G; Wicquart L; Leteurtre E; Trésallet C; Marlow LA; Copland JA; Durante C; Maenhaut C; Cavaco BM; Dumont JE; Costante G; Roger PP
Front Endocrinol (Lausanne); 2023; 14():1247542. PubMed ID: 37964967
[TBL] [Abstract] [Full Text] [Related]
11. Identification of UBFD1 as a prognostic biomarker and molecular target among estrogen receptor-positive breast cancer.
Duan L; Liu R; Cui X; Zhang Q; Cao D; Chen M; Zhang A
Biochem Biophys Res Commun; 2023 Dec; 686():149171. PubMed ID: 37922573
[TBL] [Abstract] [Full Text] [Related]
12. Therapeutic, diagnostic and prognostic values of TRIM proteins in prostate cancer.
Li X; Bai Y; Feng K; Chu Z; Li H; Lin Z; Tian L
Pharmacol Rep; 2023 Dec; 75(6):1445-1453. PubMed ID: 37921966
[TBL] [Abstract] [Full Text] [Related]
13. Usefulness of second 131I treatment in biochemical persistent differentiated thyroid cancer patients.
Gambale C; Prete A; Contartese L; Torregrossa L; Bianchi F; Molinaro E; Materazzi G; Elisei R; Matrone A
Eur Thyroid J; 2023 Dec; 12(6):. PubMed ID: 37855417
[TBL] [Abstract] [Full Text] [Related]
14. BRAF
Cao J; Chen B; Zhu X; Sun Y; Li X; Zhang W; Wang X
Endocrine; 2024 Apr; 84(1):160-170. PubMed ID: 37851243
[TBL] [Abstract] [Full Text] [Related]
15. Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study.
Han N; Lu C; Li J; Wang C; Zhao Z; Zhang Y; Liu X; Si Z; Wang G; Wang Z; Li F; Wang X
Front Endocrinol (Lausanne); 2023; 14():1222470. PubMed ID: 37810895
[TBL] [Abstract] [Full Text] [Related]
16. Random Forest for Predicting treatment Response to Radioiodine and Thyrotropin Suppression Therapy in Patients With Differentiated thyroid cancer But Without Structural Disease.
Sa R; Yang T; Zhang Z; Guan F
Oncologist; 2024 Jan; 29(1):e68-e80. PubMed ID: 37669005
[TBL] [Abstract] [Full Text] [Related]
17. Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy.
Wang C; Lu G; Li Y; Liu X; Wang G; Lu C; Li J; Luo Q; Zhang Q; Sun M; Wang X; Wang R
Front Endocrinol (Lausanne); 2023; 14():1217092. PubMed ID: 37600705
[TBL] [Abstract] [Full Text] [Related]
18. Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06).
Masuyama M; Masuda N; Kawaguchi H; Yamamoto Y; Saji S; Nakayama T; Aogi K; Anan K; Ohtani S; Sato N; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita T; Yotsumoto D; Toi M; Ohno S
Cancer Med; 2023 Sep; 12(17):17718-17730. PubMed ID: 37525895
[TBL] [Abstract] [Full Text] [Related]
19. Lung cancer with breast metastasis: a case report and review of the literature.
Cao X; Chen P; Agyekum EA; Zhang Q; Qian X; Wu T; Chambers KH; Yin L
J Int Med Res; 2023 Jul; 51(7):3000605231188287. PubMed ID: 37523488
[TBL] [Abstract] [Full Text] [Related]
20. Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast cancer.
Zhang Y; Lv L; Zheng R; Xie R; Yu Y; Liao H; Chen J; Zhang B
Breast Cancer Res; 2023 Jun; 25(1):75. PubMed ID: 37365643
[TBL] [Abstract] [Full Text] [Related]
[Next]
